Cecilia Renzulli
Overview
Explore the profile of Cecilia Renzulli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abell T, Kuo B, Esfandyari T, Pfeifer N, Grimaldi M, Renzulli C, et al.
Neurogastroenterol Motil
. 2023 Jan;
35(4):e14523.
PMID: 36624727
Background: This study assessed the efficacy and safety of velusetrag-a 5-HT agonist with pan-gastrointestinal prokinetic activity-for gastroparesis symptom management and gastric emptying (GE). Methods: In this multicenter, double-blind, randomized, placebo-controlled...
2.
Ble A, Renzulli C, Cenci F, Grimaldi M, Barone M, Sedano R, et al.
J Crohns Colitis
. 2021 Sep;
16(3):490-499.
PMID: 34508572
Background And Aims: We aimed to quantify the magnitude of the association between endoscopic recurrence and clinical recurrence [symptom relapse] in patients with postoperative Crohn's disease. Methods: Databases were searched...
3.
Kuo B, Barnes C, Nguyen D, Shaywitz D, Grimaldi M, Renzulli C, et al.
Aliment Pharmacol Ther
. 2021 Jun;
54(2):185-186.
PMID: 34170530
No abstract available.
4.
Kuo B, Barnes C, Nguyen D, Shaywitz D, Grimaldi M, Renzulli C, et al.
Aliment Pharmacol Ther
. 2021 Apr;
53(10):1090-1097.
PMID: 33811761
Background: Gastroparesis is a serious gastrointestinal (GI) condition characterised by delayed gastric emptying (GE). Velusetrag-a potent, selective, pan-gastrointestinal 5-hydroxytryptamine type 4 receptor agonist-is under investigation for treatment of GI motility...
5.
Colucci R, Pellegrini C, Fornai M, Tirotta E, Antonioli L, Renzulli C, et al.
Front Pharmacol
. 2018 Dec;
9:1340.
PMID: 30555323
Non-steroidal anti-inflammatory drugs (NSAIDs) can damage the small intestine, mainly through an involvement of enteric bacteria. This study examined the pathophysiology of NSAID-associated intestinal lesions in a rat model of...
6.
Scarpignato C, Dolak W, Lanas A, Matzneller P, Renzulli C, Grimaldi M, et al.
Gastroenterology
. 2016 Dec;
152(5):980-982.e3.
PMID: 28007576
The intestinal microbiota might contribute to enteropathy associated with use of nonsteroidal anti-inflammatory drugs (NSAIDs), but there have been few human studies of this association. We performed a placebo-controlled study...
7.
Fornai M, Antonioli L, Pellegrini C, Colucci R, Sacco D, Tirotta E, et al.
Pharmacol Res
. 2016 Jan;
104:186-96.
PMID: 26747402
Nonsteroidal anti-inflammatory drugs, besides exerting detrimental effects on the upper digestive tract, can also damage the small and large intestine. Although the underlying mechanisms remain unclear, there is evidence that...
8.
Calanni F, Renzulli C, Barbanti M, Viscomi G
J Antibiot (Tokyo)
. 2014 Aug;
67(9):667-70.
PMID: 25095806
Rifaximin is a non-systemic oral antibiotic derived from rifampin and characterized by a broad spectrum of antibacterial activity against Gram-positive and -negative, aerobic and anaerobic bacteria. Rifaximin was first approved...
9.
Calanni F, Renzulli C, Fogli M, Barbanti M
J Clin Gastroenterol
. 2013 Jun;
47(9):814.
PMID: 23751850
No abstract available.
10.
Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, et al.
Drug Metab Dispos
. 2010 Nov;
39(2):215-27.
PMID: 21045199
N-[[(2S)-1-[[5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl]-2-piperidinyl]methyl]-4-benzofurancarboxamide (SB-649868) is a novel orexin 1 and 2 receptor antagonist under development for insomnia treatment. The disposition of [(14)C]SB-649868 was determined in eight healthy male subjects using an open-label...